Elevate your local knowledge

Sign up for the iNFOnews newsletter today!

Select Region

Selecting your primary region ensures you get the stories that matter to you first.

Pfizer, Takeda settle Protonix patent case with generic drugmakers for $2.15 billion

NEW YORK, N.Y. – Pfizer says it has reached a $2.15 billion settlement with a couple of generic drugmakers over sales of their versions of the heartburn drug Protonix.

The world’s second-largest drugmaker says Teva Pharmaceutical Industries will pay $1.6 billion to Pfizer and Japanese drugmaker Takeda Pharmaceutical.

Another generic drugmaker, Sun Pharmaceutical Industries, will pay $550 million.

Teva is one of the world’s largest generic drugmakers. It started selling its generic version of Protonix in December 2007. Sun launched its own version in early 2008. The drug’s U.S. patent expired in 2011.

Drugmaker Nycomed developed Protonix before the company was purchased by Takeda. Nycomed licensed Protonix to Wyeth, which Pfizer has since purchased.

Pfizer says it will receive 64 per cent of the settlement proceeds.

News from © The Associated Press, . All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.

Join the Conversation!

Want to share your thoughts, add context, or connect with others in your community?

Create a free account

The Associated Press

The Associated Press is an independent global news organization dedicated to factual reporting. Founded in 1846, AP today remains the most trusted source of fast, accurate, unbiased news in all formats and the essential provider of the technology and services vital to the news business. More than half the world’s population sees AP journalism every day.

Related Articles